Keyphrases
Medicare Advantage
100%
Diabetes Medications
100%
Commercial Insurance
100%
Glucagon-like peptide-1 (GLP-1)
75%
Receptor Agonist
75%
A1 Receptor
75%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
75%
Dipeptidyl peptidase-4 (DPP-4)
50%
Type 2 Diabetes Mellitus (T2DM)
25%
Health Plans
16%
Commercially Insured
16%
Glucose Level
16%
Low Glucose
16%
Inhibitor Treatment
16%
Older Adults
8%
Hypoglycemia
8%
Cardiovascular Outcomes
8%
Diabetes Management
8%
New Drugs
8%
Treatment Decisions
8%
Retrospective Cohort Study
8%
Postmarketing
8%
Drug Class
8%
Low-income Patients
8%
Odds Ratio
8%
Clinical Factors
8%
Agonist Treatment
8%
Between-group
8%
Low Dose Rate
8%
Demographic Factors
8%
Administrative Claims Data
8%
Adjusted Rates
8%
Logistic Regression Model
8%
Treatment Initiation
8%
Health Insurance Plans
8%
Initiation Rate
8%
Kidney Outcomes
8%
Medication Initiation
8%
Non-clinical Factors
8%
Medication Prescription
8%
Medicine and Dentistry
Medicare
100%
Diabetes
100%
Drug Therapy
100%
Receptor
75%
Sodium Glucose Cotransporter 2 Inhibitor
75%
Dipeptidyl Peptidase-4 Inhibitor
50%
Maturity Onset Diabetes of the Young
25%
Cardiovascular System
8%
Hypoglycemia
8%
Retrospective Cohort Study
8%
Logistic Regression Analysis
8%
Prescription Medication
8%
Odds Ratio
8%
Nursing and Health Professions
Medicare
100%
Drug Therapy
100%
Receptor
75%
Sodium Glucose Cotransporter 2 Inhibitor
75%
Dipeptidyl Peptidase IV Inhibitor
50%
Non Insulin Dependent Diabetes Mellitus
25%
Glucose Level
16%
Odds Ratio
8%
Independent Practice Association
8%
Cohort Analysis
8%
Logistic Regression Analysis
8%
Hypoglycemia
8%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor Agonist
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Dipeptidyl Peptidase IV Inhibitor
66%
Non Insulin Dependent Diabetes Mellitus
33%
Cohort Study
11%
Prescription Medication
11%
Hypoglycemia
11%